- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Racura doses first patient in lung cancer combination trial | 1 | Investing.com | ||
| Do | Racura Oncology Treats First Patient in Harness-1 EGFRm Lung Cancer Trial | 1 | smallcaps.com.au | ||
| Mi | RACURA ONCOLOGY LTD: Racura Treats First Patient in HARNESS-1 Lung Cancer Trial | - | ASX | ||
| 16.06. | Racura Oncology Secures A$34.3 Million to Propel Clinical Trials | 1 | Finance News Network | ||
| 16.06. | RACURA ONCOLOGY LTD: Racura Oncology Investor Briefings Perth & Auckland | - | ASX | ||
| 16.06. | RACURA ONCOLOGY LTD: Racura raised $34.3m to Advance Three Oncology Trials | - | ASX | ||
| 16.06. | RACURA ONCOLOGY LTD: Cleansing Notice | - | ASX | ||
| 16.06. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| RACURA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 11.06. | RACURA ONCOLOGY LTD: Cleansing Notice | - | ASX | ||
| 11.06. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 08.06. | RACURA ONCOLOGY LTD: Appendix 3Y-Dr Serge Scrofani | - | ASX | ||
| 04.06. | Racura Oncology Secures $24.38 Million from High Option Exercise Rate | 1 | Finance News Network | ||
| 04.06. | Thursday's HotCopper trends: Racura, Locksley, Elixir Energy, and other daily topics | 2 | The Market Online Australia | ||
| 04.06. | Daily Special: Immutep, Bayan Mining and Minerals, Racura Oncology, Lac Gold | 2 | Finance News Network | ||
| 04.06. | Why Chrysos, Endeavour, Racura, and Treasury Wine shares are racing higher today | 1 | The Motley Fool Australia | ||
| 04.06. | RACURA ONCOLOGY LTD: Racura Options Raised $24.4m | - | ASX | ||
| 04.06. | RACURA ONCOLOGY LTD: Notification of cessation of securities - RAC | - | ASX | ||
| 03.06. | RACURA ONCOLOGY LTD: Proposed issue of securities - RAC | - | ASX | ||
| 03.06. | RACURA ONCOLOGY LTD: Emerging Companies Specialist Invests in Racura | - | ASX | ||
| 01.06. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX |
1 2 3 4 5 Weiter >>
89 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 132,66 | +0,04 % | Deal Dispatch: Penske Buys Vox Media's Digital Brands, AbbVie Acquires Apogee Therapeutics For $10.9 Billion, Camp Mystic Bankruptcy | ||
| PRAXIS PRECISION MEDICINES | 349,93 | -0,18 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 32,550 | -0,03 % | Jefferies upgrades Tango Therapeutics stock rating on cancer trial data | ||
| QIAGEN | 34,570 | +0,74 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für Qiagen von 38 auf 40 Euro angehoben und die Einstufung auf "Kaufen" belassen. Das Thema Künstliche Intelligenz (KI) sei für den Life-Science-Zuliefersektor... ► Artikel lesen | |
| VERA THERAPEUTICS | 43,130 | -0,05 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 109,43 | +0,10 % | Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS? | OTTAWA (dpa-AFX) - Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which... ► Artikel lesen | |
| ERASCA | 18,290 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,740 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress | - JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor, CGT1145... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 35,340 | 0,00 % | Harmony Biosciences Stock Outlook as Wakix Growth Meets Pipeline | ||
| MINERALYS THERAPEUTICS | 26,880 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 62,41 | 0,00 % | Kiniksa Pharmaceuticals Aktie markiert Rekordhoch bei 59,89 USD | ||
| ABSCI | 11,345 | -0,04 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,310 | -0,07 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| RELAY THERAPEUTICS | 19,740 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| BEAM THERAPEUTICS | 34,950 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen |
RACURA ONCOLOGY LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,040 (+2,94 %) liegt der Kurs bei 1,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RACURA ONCOLOGY LTD finden Sie auf Wallstreet Online.